Dupixent and Cancer: 10 FAQs Dogmatically Answered

Serious Dupixent Side Effects: The medication can cause serious side effects, including:

• Allergic reactions. Dupixent can cause allergic reactions, including skin reactions, that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, skin rash, including rash that looks like a bullseye or painful red or blue bumps under the skin, general ill feeling, itching, swollen lymph nodes, nausea or vomiting, joint pain, or cramps in your stomach area.

• Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed.

• Joint aches and pain. Some people who use Dupixent have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop Dupixent if you develop joint symptoms.

2. What Are the Symptoms of CTCL?

Symptoms of CTCL may include:

1. Itching
2. Red, scaly, or thickened patches of skin
3. Peeling skin
4. Discolored skin
5. Raised bumps or nodules
6. Skin sores or ulcers
7. Hair loss
8. Enlarged lymph nodes

3. Are there Patient Reports of Cancer Linked to Dupixent?

• Patient and Healthcare Reports on FAERS: In addition to the clinical research and studies, the U.S. Federal and Drug Administration’s (FDA),  Adverse Event Reporting System (FAERS) included numerous patient reports and reports from healthcare providers linking Dupixent (dupilumab) to cancer, specifically to multiple types of T-cell lymphoma. FAERS is a vital database that regulators and researchers use to recognize potential drug risks requiring further investigation.

• Reports Confirm Clinical Research: As you will note by visiting FAERS from the button below, the current dashboard shows close to 300 reports of T-cell lymphoma cases among Dupixent patients, which includes confirmed reports of cutaneous T-cell lymphoma (CTCL) and other related and serious conditions. These patient and healthcare reports to the FDA continue to fuel concerns that was addressed in clinical studies, strengthening the need for doctors to closely monitoring patients taking Dupixent.

• The database shows the following type of cases have been reported by patients taking Dupixent or reported by healthcare providers:

• • Cutaneous T-Cell Lymphoma
  • Adult T-Cell Lymphoma/Leukemia
  • T-Cell Lymphoma (general)
  • CTCL, Stage IV
  • CTCL, Stage III
  • Angioimmunoblastic T-Cell Lymphoma
  • CTCL, Stage I
  • Recurrent T-Cell Lymphoma
  • Lymphoma (unspecified)
  • Anaplastic Large Cell Lymphoma (T- and null-cell types)
  • Unclassifiable T-Cell Lymphoma

Volume of Reports:  The vast volume of these reports only provides further evidence that Dupixent may be contributing to serious cancer risks in certain patients.